Table 3.
The incidence of specific TRAEs, grade ≥3 TRAEs.
| TRAE Name | Subgroup | Sourcea | TRAE | Grade ≥3 TRAE | ||
|---|---|---|---|---|---|---|
| Heterogeneity | Rate (95% CI) % | Heterogeneity | Rate (95% CI) % | |||
| Total TRAE | Anti-PD-1 | 13-15,22,24-26 | Random | 61.9 (37.9-85.9) | Fixed | 16.7 (14.4-19.0) |
| Pembrolizumab | 13,24,26 | Random | 50.7 (32.6-68.7) | Fixed | 16.2 (12.9-19.6) | |
| Nivolumab | 15,22 | —— | 85.0 (76.3-93.7) | Fixed | 19.5 (14.8-24.2) | |
| Camrelizumab | 14,25 | —— | —— | Fixed | 15.0 (10.7-19.4) | |
| Rash | Anti-PD-1 | 15,22,25,26 | Fixed | 10.8 (7.5-14.2) | Fixed | 1.1 (-0.2-2.4) |
| Pembrolizumab | 26 | —— | 13.0 (-0.7-26.7) | —— | 0.4 (-0.4-12.0) | |
| Nivolumab | 15,22 | Fixed | 10.8 (7.1-14.5) | —— | 1.0 (-0.3-2.3) | |
| Camrelizumab | 25 | —— | 10 (-0.7-20.7) | —— | 0 | |
| Hypothyroidism | Anti-PD-1 | 13,14,24-26 | Random | 10.1 (5.4-14.7) | —— | 0 |
| Pembrolizumab | 13,24,26 | Random | 7.6 (3.6-11.5) | —— | 0 | |
| Camrelizumab | 14,25 | Fixed | 16.5 (12.0-21.0) | —— | 0 | |
| Fatigue | Anti-PD-1 | 13,15,22,24-26 | Fixed | 9.3 (7.3-11.4) | Fixed | 0.8 (0.1-1.5) |
| Pembrolizumab | 13,24,26 | Fixed | 10.6 (7.8-13.4) | —— | 0.6 (-0.3-1.5) | |
| Nivolumab | 15,22 | Fixed | 8.0 (4.8-11.2) | Fixed | 1.1 (-0.1-2.4) | |
| Camrelizumab | 25 | —— | 6.7 (-2.2-15.6) | —— | 0 | |
| Asthenia | Anti-PD-1 | 13,14,26 | Fixed | 7.0 (4.2-9.8) | Fixed | 1.2 (0.3-2.1) |
| Pembrolizumab | 13,26 | Fixed | 6.7 (4.0-9.3) | —— | 1.3 (0.0-2.6) | |
| Camrelizumab | 14 | —— | 9.0 (5.3-9.6) | —— | 1.0 (-0.3-2.3) | |
| Decreased appetite | Anti-PD-1 | 13-15,22,26 | Fixed | 7.0 (5.2-8.7) | Fixed | 0.8 (0.1-1.5) |
| Pembrolizumab | 13,26 | Fixed | 8.0 (5.1-10.9) | —— | 0.6 (-0.3-1.5) | |
| Nivolumab | 15,22 | Fixed | 8.2 (5.0-11.5) | Fixed | 1.2 (-0.1-2.5) | |
| Camrelizumab | 14 | —— | 5.0 (2.2-7.8) | —— | 0 | |
| Diarrhea | Anti-PD-1 | 13-15,22,24-25 | Fixed | 6.0 (4.5-7.6) | Fixed | 0.8 (0.2-1.4) |
| Pembrolizumab | 13,24 | Fixed | 5.3 (3.2-7.3) | Fixed | 0.6 (-0.1-1.4) | |
| Nivolumab | 15 | —— | 11.0 (6.8-15.2) | —— | 1.0 (-0.3-2.3) | |
| Camrelizumab | 14,25 | Fixed | 5.3 (2.6-8.1) | —— | 1.0 (-0.3-2.3) | |
| Anemia | Anti-PD-1 | 13-15,24-25 | Random | 4.7 (1.4-8.1) | Fixed | 1.8 (0.8-2.7) |
| Pembrolizumab | 13 | —— | 2.5 (0.8-4.2) | —— | 1.3 (0.0-2.6) | |
| Nivolumab | 15 | —— | 3.0 (0.7-5.3) | —— | 2.0 (0.1-3.9) | |
| Camrelizumab | 14,25 | Random | 7.6 (0.1-15.1) | —— | 3.0 (0.8-5.2) | |
| Nausea | Anti-PD-1 | 13-15,25 | Random | 3.0 (1.8-4.1) | —— | 0 |
| Pembrolizumab | 13 | —— | 7.0 (4.2-9.8) | —— | 0 | |
| Nivolumab | 15 | —— | 2.0 (0.1-3.9) | —— | 0 | |
| Camrelizumab | 15,22 | Fixed | 2.2 (0.4-4.0) | —— | 0 | |
| Pneumonia | Anti-PD-1 | 14,22,24-26 | Random | 2.7 (-0.5-5.9) | Random | 0.5 (-0.2-1.2) |
| Pembrolizumab | 24,26 | Fixed | 6.5 (2.5-10.5) | —— | 2.4 (-0.3-5.1) | |
| Nivolumab | 22 | —— | 2.0 (-1.4-5.4) | —— | 0 | |
| Camrelizumab | 14,25 | —— | 0.3 (-0.4-1.0) | Fixed | 0.3 (-0.4-1.0) | |
| Vomiting | Anti-PD-1 | 13,14 | Random | 2.0 (-0.2-4.1) | —— | 0.3 (-0.3-0.9) |
| Pembrolizumab | 13 | —— | 3.2 (1.3-5.1) | —— | 0.3 (-0.3-0.9) | |
| Camrelizumab | 14 | —— | 1.0 (-0.2-4.1) | —— | 0 | |
| Neutrophil count decreased | Anti-PD-1 | 13-15,22 | Random | 1.1 (0.4-1.9) | Fixed | 0.5 (-0.1-1.0) |
| Pembrolizumab | 13 | —— | 0.6 (-0.3-1.5) | —— | 0.3 (-0.3-0.9) | |
| Nivolumab | 15,22 | —— | 2.0 (0.1-3.9) | Fixed | 1.1 (-0.1-2.4) | |
| Camrelizumab | 14 | —— | 4.0 (1.5-6.5) | —— | 0 | |
| Alopecia | Anti-PD-1 | 13-15,24,26 | Fixed | 0.7 (-0.0-1.4) | —— | 0 |
| Pembrolizumab | 13,24,26 | —— | 0.6 (-0.3-1.5) | —— | 0 | |
| Nivolumab | 15 | —— | 1.0 (-0.3-2.3) | —— | 0 | |
| Camrelizumab | 14 | —— | 0 | —— | 0 | |
TRAE, treatment-related adverse event; aSource appertain to corresponding references.